Rx Error Reduction May Need Reduced Prescriber Autonomy - Woodcock
Executive Summary
Stricter prescribing regulations may be one way to reduce the number of preventable adverse drug events, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, suggested Nov. 17.
You may also be interested in...
Clinical Trial Limits Must Be Acknowledged In ADR Debate - FDA's Lumpkin
Reform of the pharmaceutical adverse event monitoring system must be based on a larger debate over the societal expectations for clinical research, Center for Drug Evaluation & Research Deputy Director Murray Lumpkin, MD, told a Drug Information Association/ General Accounting Office panel Feb. 24 in Washington, D.C.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials